- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 10.07. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 09.06. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.04. | Cyclerion Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.04. | Cyclerion Therapeutics, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 02.04. | Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? | 7 | Barchart.com | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | - | pharmaphorum | ||
| 01.04. | Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name | 3 | Contract Pharma | ||
| 01.04. | Cyclerion Therapeutics: $380 Million Financing To Merge With Korsana Biosciences And Advance Alzheimer's Pipeline | 1 | pulse2.com | ||
| 01.04. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public | 3 | FierceBiotech | ||
| 01.04. | Morning Market Movers: Cyclerion Therapeutics, Binah Capital Group, Target Hospitality Corp., nCino See Big Swings | 896 | AFX News | WASHINGTON COUNTY (dpa-AFX) - At 8:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before... ► Artikel lesen | |
| 01.04. | Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. Announce Merger Agreement | 267 | Business Wire | Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana's lead program KRSA-028 is a next-generation... ► Artikel lesen | |
| 16.03. | Korsana Biosciences Taps Dr. Mark Vignola as CFO | 1 | Contract Pharma | ||
| 22.02. | Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer's Drug | 1 | MedCity News | ||
| 18.02. | Korsana Biosciences Raises $175M in Funding | 1 | FinSMEs | ||
| 17.02. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.02. | Cyclerion receives FDA feedback on depression treatment development | 6 | Investing.com | ||
| 05.01. | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | 192 | GlobeNewswire (Europe) | - Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer - - Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept... ► Artikel lesen | |
| 23.09.25 | Cyclerion Therapeutics, Inc.: Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company | 326 | GlobeNewswire (Europe) | - Cyclerion Relaunches, Advancing a Phase 2-Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement - - Webcast to be held September 24, 2025 at 10:30 a.m.... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,666 | -1,05 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| EDITAS MEDICINE | 2,550 | +2,41 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,236 | +0,98 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,168 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,833 | -3,48 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,215 | -0,16 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,340 | +3,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,000 | +2,52 % | DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum | ||
| CEL-SCI | 1,500 | +2,74 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| CYTOKINETICS | 66,28 | -0,12 % | Cytokinetics, Incorporated: Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update | MYQORZO- (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,098 | +0,27 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $13.6 million in Q2 2026, up 15% over Q1 - - Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer -... ► Artikel lesen | |
| CURIS | 3,405 | 0,00 % | Curis, Inc.: Curis Doses First Five Patients in TakeAim CLL Study | LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,929 | +0,83 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen |
CYCLERION THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,570 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.